Huili Lu
  • Faculty, Shanghai Jiao Tong University
Research focus
  • Biotechnology and Bioengineering
  • recombinant proteins, antibody drug, stem cell therapy
  • 1 Author merit

Education

Ph.D., Shanghai Jiao Tong University, 2007

Publications

• Luo M, Zhao M, Cagliero C, Jiang H, Xie Y, Zhu J, Yang H, Zhang M, Zheng Y, Yuan Y, Du Z, Lu H*. A general platform for efficient extracellular expression and purification of Fab from Escherichia coli. Appl Microbiol Biotechnol. 2019 Mar 6. Doi: 10.1007/s00253-019-09745-8
• Zhao M, Luo M, Xie Y, Jiang H, Cagliero C, Li N, Ye H, Wu M, Hao S, Sun T, Yang H, Zhang M, Lin T, Lu H*, Zhu J*. Development of a recombinant human IL-15·sIL-15Rα/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model. Biomedicine & Pharmacotherapy. 2019 Feb 21;112:108677. Doi: 10.1016/j.biopha.2019.108677
• Zhao M, Wang J, Luo M, Luo H, Zhao M, Han L, Zhang M, Yang H, Xie Y, Jiang H, Feng L, Lu H*, Zhu J*. Rapid development of stable transgene CHO cell lines by CRISPR/Cas9-mediated site-specific integration into C12orf35. Appl Microbiol Biotechnol. 2018 May 22; 102(14), 6105-6117. doi: 10.1007/s00253-018-9021-6
• Chen H, Li N, Xie Y, Jiang H, Yang X, Cagliero C, Shi S, Zhu C, Luo H, Chen J, Zhang L, Zhao M, Feng L, Lu H*, Zhu J*. Purification of Inclusion Bodies Using PEG Precipitation under Denaturing Conditions to Produce Recombinant Therapeutic Proteins from Escherichia coli. Appl Microbiol Biotechnol. 2017 Apr 8. 101(13), 5267-5278. DOI: 10.1007/s00253-017-8265-x
• Shi S, Chen H, Jiang H, Xie Y, Zhang L, Li N, Zhu C, Chen J, Luo H, Wang J, Feng L, Lu H*, Zhu J*. A novel self-cleavable tag Zbasic-∆I-CM and its application in the soluble expression of recombinant human interleukin- 15 in Escherichia coli. Appl Microbiol Biotechnol. 2017 Feb;101(3), 1133-1142. DOI: 10.1007/s00253-016-7848-2
• Sun T, Li C, Han L, Jiang H, Xie Y, Zhang B, Qian X, Lu H*, Zhu J*. Functional knockout of FUT8 in Chinese hamster ovary cells using CRISPR/Cas9 to produce a defucosylated antibody. Eng Life Sci. 2015 Sep;15(6): 660–666. Doi: 10.1002/elsc.201400218.
• Lu H, Liu H, Wang J, Shen J, Weng S, Han L, Sun T, Qian L, Wu M, Zhu S, Yu Y, Han W, Zhu J, Moldenhauer A. The Chemokine CXCL9 Exacerbates Chemotherapy-induced Acute Intestinal Damage through Inhibition of Mucosal Restitution. J Cancer Res Clin Oncol. 2015 Jun;141(6):983-92. Doi: 10.1007/s00432-014-1869-y
• Lu H, Zhu S, Qian L, Xiang D, Zhang W, Nie A, Gao J, Wu M, Gao J, Lu B, Yu Y, Han W, Moldenhauer A. Activated expression of the chemokine Mig after chemotherapy contributes to chemotherapy-induced bone marrow suppression and lethal toxicity. Blood 2012; May 24;119(21):4868-77. doi: 10.1182/blood-2011-07-367581
• Qian L, Zhu S, Shen J, Han X, Gao J, Wu M, Lu H*, Han W. Expression and purification of recombinant human Mig in Escherichia coli and its comparison with murine Mig. Protein Expr Purif 2012 Jan; 82(1): 205-211.
1 Protocol published
A PhoA-STII Based Method for Efficient Extracellular Secretion and Purification of Fab from Escherichia coli
Authors:  Ziyan Wang, Yang Gao, Manyu Luo, Cedric Cagliero, Hua Jiang, Yueqing Xie, Jianwei Zhu and Huili Lu, date: 09/20/2019, view: 221, Q&A: 0
In comparison with full-length IgGs, antigen binding fragments (Fabs) are smaller in size and do not require the complexed post-translational modification. Therefore, Fab can be cost-effectively produced using an Escherichia coli (E. coli ...
We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.